Reporting in the journal Genes and Development, investigators have developed a simple way to use the RNAi approach to silence a selected gene in a specific tissue in a mouse to determine the function of that targeted gene.
Previously reported approaches to achieve this were either technically cumbersome, not generally applicable, or only achieved transient knockdown of the target gene.
"Having a tool that will allow us to knockdown the expression of any given gene in any specific tissue or cell type represents a significant advance in the field," says the study's lead investigator, Miles Wilkinson, Ph.D., a professor in the Department of Immunology.
For example, this method could potentially be used in humans "to knockdown the expression of mutant or overexpressed genes that cause human diseases, including cancer," Wilkinson says. "Scientists and clinicians can use it to reduce the expression of the target gene in a single or limited numbers of cell types or tissues, thereby reducing side effects."
Equally, the technique can help researchers determine the function of a single gene in a single tissue, which "is potentially a powerful investigative tool," Wilkinson says. "By silencing a particular gene in a specific tissue, you can learn what the function of that gene is in that particular tissue without blocking its essential functions in other tissues."
In their study, Wilkinson and his research team demonstrated how well their tool worked by silencing the WT1 tumor suppressor gene in the testes of mice. They found this gene is important in the production of healthy sperm by encoding a regulatory protein called a transcription factor that controls the formation of adherens junctions, or the cell-to-cell contacts between nurse cells and the germ cells that ultimately become sperm.
Using RNAi to silence WT1, therefore, led to the discovery that WT1 is the first transcription factor shown to regulate the formations of these junctions, Wilkinson says. "It is a transcription factor that dictates both the formation of the testes in the embryo, and the function of the testes after birth."
Researchers worldwide have been trying to harness the power of RNAi since it was discovered in 1998. RNAi rocked the world of science because of the vast implications this natural cellular control system potentially offered medicine.
RNAi is used by cells in many life forms to identify viral RNA, which often enters a cell as a double strand. The organism's own RNA, however, leaves the nucleus of cells (where it was produced by DNA) as a single strand, to be decoded by ribosomes into the proteins that perform all the work of the cell. RNAi, therefore, recognizes the double strand of viral RNA as different, and sets in motion cell machinery that destroys the invading RNA. This involves cutting up the double-stranded RNA, separating it into single strands, and destroying other single-stranded RNA molecules that are complementary to those small RNA segments.
Scientists quickly realized that if they could produce a double-stranded RNA that mimics the RNA produced by a gene they wish to silence, RNAi would do the job for them. Producing the decoy "small RNAs" that trigger RNAi has become a fairly simple process, Wilkinson says, but the difficulty has been to use these matches only in specific tissues, and to figure out a way to make this "treatment" last. The work by the M. D. Anderson team has come up with a solution that solves both problems.
The technique they developed involves use of two different "modules" that can be swapped in and out of the backbone of a vector. One is a small stem loop designed to complement the RNA produced by the gene they wish to silence, and the other is a "promoter" that provides expression specific to the tissue they want to target. "There are whole batteries of different promoters, ones specifically for skin, or different parts of the brain, or whatever organ or tissue you are likely to want," Wilkinson says. "By swapping out either of these modules, you have the potential to silence any gene in any tissue you might want," he said.
In their study, the researchers made a vector with a promoter specific for nurse cells in the testis, so that the small RNA that is associated with WT1 is only made in this cell type, thereby reducing WT1 levels that are only in the nurse cells. Other organs, like kidney, that need WT1 to function are not affected, Wilkinson says.
"We are very excited about the potential of this approach, and hope that is solves what had become a significant roadblock to effective use of RNAi," he says.
The study was funded by the National Institutes of Health. The co-authors from M. D. Anderson Cancer Center are Manjeet Rao, Ph.D., John Pham, J. Saadi Iman, James MacLean, Ph.D., Deepa Murali, Ph.D., and Yashudi Furuta, Ph.D., Amiya Sinha-Hilim, Ph.D., from the UCLA School of Medicine also contributed.